SEARCH

SEARCH BY CITATION

References

  • Anon. (2005a) A 10-week, randomized, double-blind, multicenter, placebo-controlled study of pregabalin and paroxetine in the treatment of panic disorder. Protocol No. 1008-091 PhRMA Clinical study Synopsis 6 July 2005.
  • Anon. (2005b) A randomized, double-blind, parallel group, placebo and lamotrigine controlled, multicenter study in patients with partial seizures. Protocol No.1008-112 Clinical study Synopsis 14 July 2005.
  • Anon. (2005c) Sustained efficacy study of pregabalin in patients with panic disorder with or without agoraphobia. Protocol No. 1008-093 PhRMA Clinical study Synopsis 14 July 2005.
  • Anon. (2005d) Pregabalin BID add-on trial: a randomized, double-blind, placebo-controlled parallel-group single-center sleep EEG study in patients with partial seizures and sleep disturbance. Protocol 1008-000-167 Part B PhRMA Clinical Study Synopsis - 7 September 2005.
  • Anon. (2007a) A placebo-controlled trial of pregabalin and amitriptyline for treatment of painful diabetic peripheral neuropathy. Protocol No. 1008-040 PhRMA Clinical study Synopsis 14 July 2007.
  • Anon. (2007b) A placebo-controlled study of pregabalin in elderly patients with generalized anxiety disorder. Protocols 1008-0090, 1008-0152. PhRMA Clinical study Synopsis 12 September 2007.
  • Anon. (2007c) A randomized, double-blind, placebo-controlled, parallel-group, multi-center trial of pregabalin versus placebo in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Protocol No. A0081071 Clinical study Synopsis 19 December 2007.
  • Anon. (2007d) A 14-week, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of pregabalin (150mg-600mg/day) using a flexible optimal dose schedule in patients with painful Diabetic Peripheral Neuropathy (DPN). Protocol No. A0081030 Clinical study Synopsis 28 December 2007.
  • Anon. (2008a) An 8 week multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of pregabalin (150mg-600mg/day) using a flexible dosing schedule in the treatment of subjects with symptoms of neuropathic pain. Protocol No. 1008-1081 PhRMA Clinical study Synopsis 17 January 2008.
  • Anon. (2008b) A 14 week, randomized, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia. Protocol No. A0081100 Clinical study Synopsis 7 March 2008.
  • Anon. (2008c) A 10-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pregabalin (150mg–600mg/Day) using a flexible, optimized dose schedule in subjects with peripheral neuropathic pain. Protocol No A008-1037 PhRMA Clinical study Synopsis 06 August 2008.
  • Anon. (2008d) A randomized, double-blind, placebo-controlled, parallel group, multi-center trial of pregabalin versus placebo in the treatment of neuropathic pain associated with HIV neuropathy. Protocol No. A0081066 Clinical study Synopsis 7 October 2008.
  • Anon. (2009a) A 9-week, randomized, double-blind, placebo-controlled, multicenter, study of pregabalin (BID) in subjects with post traumatic peripheral neuropathic pain. Protocol No. A0081064 Clinical study Synopsis 7 January 2009.
  • Anon. (2009b) A 13-week, randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of pregabalin (150-600 mg/day) using a flexible dosing schedule in the treatment of subjects with Central Post-Stroke Pain (CPSP). Protocol No. A0081063 Clinical study Synopsis 10 March 2009.
  • Anon. (2009c) A multicenter, randomized, double-blind, placebo-controlled study of pregabalin in subjects with Generalized Anxiety Disorder (GAD) switching from benzodiazepine therapy. Protocol No. A008-1092 PhRMA Clinical study Synopsis 16 April 2009.
  • Anon. (2009d) A multicenter, double-blind randomized, placebo-controlled study of the efficacy and safety of pregabalin in the treatment of subjects with post-operative pain following Total Knee Arthroplasty (TKA). Protocol No. 1008-1133 PhRMA Clinical study Synopsis 17 July 2009-d.
  • Anon. (2009e) A 13-week, randomized, double-blind, multicenter, placebo-controlled study to evaluate efficacy and safety of pregabalin (CI-1008) in the treatment of postherpetic neuralgia. Protocol No. A0081120 Clinical study Synopsis 19 August 2009.
  • Anon. (2009f) Randomized, double-blind, 6-week study of pregabalin in subjects with restless legs syndrome. Protocol No. A0081183 PhRMA Clinical study Synopsis 4 October 2009.
  • Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. (2008) Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 8:33.
  • Arnold LM, Crofford LJ, Martin SA, Young JP, Sharma U. (2007) The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 8:634638.
  • Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, Martin SA, Barrett JA, Haig G. (2008) A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9:792805.
  • Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, Messmer S. (2004) Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45:2027.
  • Ben-Menachem E. (2004) Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45(suppl 6):1318.
  • Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA, Pregabalin 1008-009 Study Group. (2005) Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64:475480.
  • Chadwick DW, Marson AG. (2000) Zonisamide for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2:CD001416. Review. Update in: Cochrane Database Syst Rev 2002;2:CD001416.
  • Chadwick DW, Marson AG. (2002) Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 4:CD001416. Review. Update in: Cochran Database Syst Rev 2005;4:CD001416.
  • Chadwick DW, Marson AG. (2005) Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 4:CD001416.
  • Chaisewikul R, Privitera MD, Hutton JL, Marson AG. (2001) Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Syst Rev 1:CD001901.
  • Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LaMoreaux LK, Martin SA, Sharma U, Pregabalin 1008-105 Study Group. (2005) Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:12641273.
  • Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, Sharma U. (2008) Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136:419431.
  • de Haas S, Otte A, de Weerd A, van Erp G, Cohen A, van Gerven J. (2007) Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. J Clin Sleep Med 3:473478.
  • Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM. (2003) Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60:12741283.
  • Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. (2005) Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 46:19261936.
  • Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC. (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23:240249.
  • Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. (2008) Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 23:1828.
  • Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. (2009) Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci 285:195197.
  • French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. (2003) Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60:16311637.
  • Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. (2005) Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115:254263.
  • Hemming K, Maguire MJ, Hutton JL, Marson AG. (2008) Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev 3:CD007302.
  • Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. (2007) Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 56:12181225.
  • Jette NJ, Marson AG, Kadir ZA, Hutton JL. (2000) Topiramate for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2:CD001417. Review. Update in: Cochran Database Syst Rev 2002;3:CD001417.
  • Jette NJ, Marson AG, Hutton JL. (2002) Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 3:CD001417. Review. Update in: Cochran Database Syst Rev 2008;3:CD001417.
  • Jette N, Hemming K, Hutton JL, Marson AG. (2008) Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 3:CD001417.
  • Johannessen Landmark C. (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22:2747.
  • Kasper S, Herman B, Nivoli G, Ameringen MV, Petralia A, Mandel FS, Baldinetti F, Bandelow B. (2009) Effitcacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 24:8796.
  • Leach JP, Marson AG, Hutton JL. (2002) Remacemide for drug-resistant localization related epilepsy. Cochrane Database Syst Rev 4:CD001900.
  • Lee BI, Yi S, Hong SB, Kim MK, Lee SA, Lee SK, Shin DJ, Kim JM, Song HK, Heo K, Lowe W, Leon T. (2009) Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial. Epilepsia 50:464474. Erratum in: Epilepsia. 2009 Aug;50(8):2010.
  • Lesser H, Sharma U, LaMoreaux L, Poole RM. (2004) Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63:21042110.
  • Liao YJ, Safa P, Chen YR, Sobel RA, Boyden ES, Tsien RW. (2008) Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo. Proc Natl Acad Sci U S A 105:27052710.
  • Lozsadi D, Hemming K, Marson AG. (2008) Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 1:CD005612.
  • Marson AG, Kadir ZA, Hutton JL, Chadwick DW. (1997) The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38:859880.
  • Marson AG, Kadir ZA, Hutton JL, Chadwick DW. (2000) Gabapentin for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2:CD001415. Review. Update in: Cochran Database Syst Rev 2000;3:CD001415.
  • Marson AG, Hutton JL, Leach JP, Castillo S, Schmidt D, White S, Chaisewikul R, Privitera M, Chadwick DW. (2001) Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 46:259270.
  • Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, Sharma U. (2008) A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35:502514.
  • Michael B, Marson AG. (2008) Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev 2:CD004154.
  • Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771782.
  • Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. (2008) Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 193:389394.
  • Nakagawasai O, Onogi H, Mitazaki S, Sato A, Watanabe K, Saito H, Murai S, Nakaya K, Murakami M, Takahashi E, Tan-No K, Tadano T. (2010) Behavioral and neurochemical characterization of mice deficient in the N-type Ca2+ channel alpha1B subunit. Behav Brain Res 208:224230.
  • Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, Liu-Dumaw M. (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160:533540.
  • Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL. (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24:141149.
  • Pereira J, Marson AG, Hutton JL. (2002) Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 3:CD001908.
  • Perucca P, Carter J, Vahle V, Gilliam FG. (2009) Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 72:12231229.
  • Pohl RB, Feltner DE, Fieve RR, Pande AC. (2005) Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25:151158.
  • Ramaratnam S, Marson AG, Baker GA. (2000) Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 3:CD001909. Review. Update in: Cochrane Database Syst Rev 2001;3:CD001909
  • RevMan. (2008) Review Manager (RevMan) [Computer program]. Version 5.0. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
  • Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6:253260.
  • Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62:10221030.
  • Rosenberg JM, Salzman C. (2007) Update: new uses for lithium and anticonvulsants. CNS Spectr 12:831841.
  • Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110:628638.
  • Ryvlin P, Perucca E, Rheims S. (2008) Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat 4:12111224.
  • Ryvlin P, Kälviäinen R, Von Raison F, Giordano S, Emir B, Chatamra K. (2010) Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS). Eur J Neurol 17:726732.
  • Sabatowski R, Gálvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M, 1008-045 Study Group. (2004) Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109:2635.
  • Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. (2006) Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 67:17921800.
  • Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. (2008) Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain 9:10061017.
  • Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. (2008) Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 12:203213.
  • U.S. Food and Drug Administration. (2010) Joint meeting of the Peripheral and Central Nervous Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee: briefing material, July 10, 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-00-index.html. Accessed May 20, 2010.
  • van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. (2006) Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 22:375384.
  • Vranken JH, Dijkgraaf MG, Kruis MR, van der Vegt MH, Hollmann MW, Heesen M. (2008) Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 136:150157.
  • Zesiewicz TA, Ward CL, Hauser RA, Salemi JL, Siraj S, Wilson MC, Sullivan KL. (2007) A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 22:16611663.
  • Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC. (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 15:6269.